Search

Your search keyword '"Rangoni, Giovanni"' showing total 27 results
Start Over Author "Rangoni, Giovanni"
27 results on '"Rangoni, Giovanni"'

1. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients

Author

Cascinu, Stefano, Rosati, Gerardo, Bilancia, Domenico, Nasti, Guglielmo, Iaffaioli, Rosario Vincenzo, Lonardi, Sara, Zagonel, Vittorina, Zaniboni, Alberto, Marchetti, Paolo, Romiti, Adriana, Leone, Francesco, Aglietta, Massimo, Giordano, Monica, Corsi, Domenico C., Ferraú, Francesco, Labianca, Roberto, Mosconi, Stefania, Ronzoni, Monica, Gianni, Luca, Rulli, Eliana, Poli, Davide, Galli, Francesca, Torri, Valter, De Simone, Irene, Galli, Fabio, Pasini, Felice, Rangoni, Giovanni, Venezia, Raffaele, Sozzi, Pietro, Nuzzo, Antonio, Berardi, Rossana, Frontini, Luciano, Rota, Silvia, Cozzi, Lorena, and Scartozzi, Mario

Published
2017
Full Text
View/download PDF

12. Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy

Author

Consoli, Francesca, primary, Manganoni, Ausilia Maria, additional, Grisanti, Salvatore, additional, Petrelli, Fausto, additional, Venturini, Marina, additional, Rangoni, Giovanni, additional, Guarneri, Francesco, additional, Incardona, Paolo, additional, Vermi, William, additional, Calzavara Pinton, Pier Giacomo, additional, and Berruti, Alfredo, additional

Published
2019
Full Text
View/download PDF

16. Abstract B16: NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with advanced NRAS-mutant melanoma who are untreated or have progressed on or after immunotherapy

Author

Long, Georgina, primary, Dummer, Reinhard, additional, Flaherty, Keith, additional, Schadendorf, Dirk, additional, Arenberger, Petr, additional, Demidov, Lev, additional, Giacomo, Anna Maria Di, additional, Mandalà, Mario, additional, Rangoni, Giovanni, additional, Wolter, Pascal, additional, Yamazaki, Naoya, additional, Ford, James, additional, Wasserman, Ernesto, additional, Weill, Marine, additional, and Ascierto, Paolo, additional

Published
2015
Full Text
View/download PDF

18. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial

Author

Ferrari, Vittorio, primary, Valcamonico, Francesca, additional, Amoroso, Vito, additional, Simoncini, Edda, additional, Vassalli, Lucia, additional, Marpicati, Patrizia, additional, Rangoni, Giovanni, additional, Grisanti, Salvatore, additional, Tiberio, Guido AM, additional, Nodari, Franco, additional, Strina, Carla, additional, and Marini, Giovanni, additional

Published
2005
Full Text
View/download PDF

19. An Alternating Regimen of Irinotecan/ 5-Fluorouracil/Folinic Acid and Oxaliplatin/ 5-Fluorouracil/Folinic Acid in Metastatic Colorectal Cancer: A Phase II Trial

Author

Ferrari, Vittorio, primary, Valcamonico, Francesca, additional, Amoroso, Vito, additional, Simoncini, Edda, additional, Vassalli, Lucia, additional, Marpicati, Patrizia, additional, Rangoni, Giovanni, additional, Grisanti, Salvatore, additional, Pasinetti, Nadia, additional, and Marini, Giovanni, additional

Published
2005
Full Text
View/download PDF

27. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients

Author

Stefano Cascinu, Gerardo Rosati, Guglielmo Nasti, Sara Lonardi, Alberto Zaniboni, Paolo Marchetti, Francesco Leone, Domenico Bilancia, Rosario Vincenzo Iaffaioli, Vittorina Zagonel, Monica Giordano, Domenico C. Corsi, Francesco Ferraú, Roberto Labianca, Monica Ronzoni, Mario Scartozzi, Francesca Galli, Adriana Romiti, Massimo Aglietta, Stefania Mosconi, Luca Gianni, Eliana Rulli, Davide Poli, Valter Torri, Irene De Simone, Fabio Galli, Felice Pasini, Giovanni Rangoni, Raffaele Venezia, Pietro Sozzi, Antonio Nuzzo, Rossana Berardi, Luciano Frontini, Silvia Rota, Lorena Cozzi, Cascinu, Stefano, Rosati, Gerardo, Bilancia, Domenico, Nasti, Guglielmo, Iaffaioli, Rosario Vincenzo, Lonardi, Sara, Zagonel, Vittorina, Zaniboni, Alberto, Marchetti, Paolo, Romiti, Adriana, Leone, Francesco, Aglietta, Massimo, Giordano, Monica, Corsi, Domenico C., Ferraú, Francesco, Labianca, Roberto, Mosconi, Stefania, Ronzoni, Monica, Gianni, Luca, Rulli, Eliana, Poli, Davide, Galli, Francesca, Torri, Valter, De Simone, Irene, Galli, Fabio, Pasini, Felice, Rangoni, Giovanni, Venezia, Raffaele, Sozzi, Pietro, Nuzzo, Antonio, Berardi, Rossana, Frontini, Luciano, Rota, Silvia, Cozzi, Lorena, and Scartozzi, Mario

Subjects
0301 basic medicine, Oncology, Male, Cancer Research, Organoplatinum Compounds, Colorectal cancer, Antibodie, Leucovorin, Cetuximab, Colorectal Neoplasm, Kaplan-Meier Estimate, 0302 clinical medicine, FOLFOX, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Humanized, Metastatic colorectal cancer, Hazard ratio, Middle Aged, Oxaliplatin, Bevacizumab, Fluorouracil, 030220 oncology & carcinogenesis, FOLFIRI, Female, Colorectal Neoplasms, medicine.drug, Human, medicine.medical_specialty, Treatment sequence, Antibodies, Monoclonal, Humanized, Irinotecan, K-RAS wild type, Treatment strategy, Aged, Camptothecin, Carcinoma, Disease-Free Survival, Humans, Antibodies, 03 medical and health sciences, Internal medicine, medicine, Antineoplastic Combined Chemotherapy Protocol, business.industry, Organoplatinum Compound, medicine.disease, digestive system diseases, 030104 developmental biology, business
Abstract

Introduction The optimal treatment strategy for RAS wild type (WT) mCRC is controversial. Our phase III study investigated the effect of introducing earlier (second-line) or later (third-line) cetuximab in patients progressed after FOLFIRI/bevacizumab first-line. Patients and methods mCRC patients progressing after FOLFIRI/bevacizumab first-line were randomised to receive second-line irinotecan/cetuximab followed by third-line FOLFOX-4 (arm A) or the reverse sequence (arm B). Primary end-point was progression-free survival (PFS). Results About 54 and 56 patients were randomised in arm A and in arm B, respectively. After a median follow-up of 37.5 months, 100 PFS events were recorded. Median PFS was 9.9 months in arm A and 11.3 months in arm B (Hazard ratio [HR] 1.04, 95% confidence interval [CI]: 0.69–1.56, p = 0.854), while median overall survival was 12.3 months in arm A and 18.6 months in arm B (HR 0.84, 95% CI: 0.55–1.28; p = 0.411). No overall difference in side-effects were observed between the two treatment arms. Conclusions This trial did not meet the primary end-point (PFS). Like other preclinical and clinical evidences, our study seems to suggest a reduced activity of cetuximab after a first-line bevacizumab-based therapy.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results